Literature DB >> 17212154

[A long term survival case of advanced intrahepatic cholangiocarcinoma treated with multidisciplinary treatment].

Toshiro Masuda1, Toru Beppu, Takatoshi Ishiko, Takao Mizumoto, Seiji Hosaka, Osamu Nakahara, Hiromitsu Hayashi, Hirohisa Okabe, Tsuyoshi Yamanaka, Kazutoshi Okabe, Hiroshi Takamori, Keiichiro Kanemitsu, Masahiko Hirota, Hideo Baba.   

Abstract

A 56-year-old man was admitted to our hospital for liver tumor of 7 cm in diameter, located mainly in the anterior segment. He underwent a hepatic resection of anterior and median segment of the liver in January 2002. Pathologically, the tumor was moderately differentiated intrahepatic cholangiocarcinoma (ICC) with vascular invasion. Hepatic arterial chemotherapy as a neoadjuvant therapy was performed. In December 2002, bone metastases in the 12th thoracic spine and iliac bone were found. Therefore, he received radiotherapy (total of 30 Gy) and a monthly bisphosphonate infusion. In May 2003, multiple intrahepatic recurrences were diagnosed. Transarterial chemoembolization for twice and an additional radio-frequency ablation were performed. Four months later, lung metastases were found, thus, he was administered TS-1. He has been alive with PS 0 for 4 and half years after the hepatic resection. No new intrahepatic recurrences were found and bone and lung metastases remained to be stable. Although only a hepatic resection is a useful therapy for ICC, such a multidisciplinary treatment may have an effect to improve the prognosis of patients with ICC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17212154

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Long-term survival after multimodal therapy in a patient demonstrating intrahepatic cholangiocarcinoma with hilar invasion and intrahepatic metastases.

Authors:  Soichiro Morinaga; Yuji Yamamoto; Nobuhiro Sugano; Hiroo Wada; Manabu Shiozawa; Makoto Akaike; Yukio Sugimasa
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.